Drug Trial Radar · NCT03219268
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
Last checked: Nov 20, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
277
Actual
Start
Aug 18, 2017
Primary completion
Feb 8, 2023
Study completion Feb 8, 2023
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- First posted
- Jul 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.
Conditions
- Advanced Solid Tumors
- Hematologic Neoplasms
- Ovarian Cancer
- HER2-positive Advanced Solid Tumors
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Cholangiocarcinoma
- Cervical Cancer
- TNBC - Triple-Negative Breast Cancer
Interventions
tebotelimab 1 mgBiological
1 mg IV every other week
tebotelimab 3 mgBiological
3 mg IV every other week
tebotelimab 10 mgBiological
10 mg IV every other week
tebotelimab 30 mgBiological
30 mg IV every other week
tebotelimab 120 mgBiological
120 mg IV every other week
tebotelimab 300 mgBiological
300 mg IV every other wee
tebotelimab 400 mgBiological
400 mg IV every other wee
tebotelimab 600 mgBiological
600 mg IV every other week
tebotelimab 800 mgBiological
800 mg IV every other week
tebotelimab 1200 mgBiological
1200 mg IV every other week
margetuximabBiological
15 mg/kg IV every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy)Time frame: up to 24 months
- Number of participants with Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (tebotelimab plus margetuximab)Time frame: up to 24 months
Locations
40 sites in 8 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
USC/Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Hematology & Oncology Clinic
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Florida Cancer Specialists & Research Institute
Sarasota, Florida
University of Chicago Medicine
Chicago, Illinois
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Massachusetts General Hospital and Dana-Farber Cancer Institute
Boston, Massachusetts
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Stephenson Cancer Center, The University of Oklahoma
Oklahoma City, Oklahoma
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
Austin Health Melbourne
Heidelberg, Victoria, Australia
"Complex Oncology Center - Burgas" EOOD
Burgas, Bulgaria
"Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda" EAD, Sofia
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment "Serdika" EOOD, Sofia
Sofia, Bulgaria
Prince of Wales Hospital
Shatin, Hong Kong
Med-Polonia Sp. z o.o.
Poznan, Poland
Pratia MCM Kraków
Krakow, Lesser Poland Voivodeship, Poland
BioVirtus Research Site Sp. Z o.o. / Biovirtus Centrum Medyczne
Józefów, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy
Warsaw, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy
Warsaw, Masovian Voivodeship, Poland
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Hospital Ruber Internacional
Madrid, Spain
START Madrid-CIOCC, Hospital HM Sanchinarro
Madrid, Spain
King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, Thailand
Songklanagarind Hospital
Songkhla, Thailand
Communal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council
Dnipro, Ukraine
Communal Nonprofit Enterprise "Prykarpatsky Clinical Oncological Centre of Ivano-Frankivska Regional Council"
Ivano-Frankivsk, Ukraine
Municipal Non-Profit Enterprise of Sumy Regional Council "Sumy Regional Clinical Oncology Dispensary"
Sumy, Ukraine
Communal Nonprofit Enterprise "Central City Clinical Hospital of Uzhhorod City Council", City Oncology Center, State Higher Educational Institution <<Uzhhorod National University>>
Uzhhorod, Ukraine
Communal Nonprofit Enterprise "Cherkassy Regional Oncology Dispensary" of Cherkassy Regional Council
Cherkassy, Cherkasy Oblast, Ukraine
Communal Nonprofit Enterprise Podillia Regional Center of Oncology of Vinnytsia Regional Council
Vinnytsia, Vinnytsa Region, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.